Senescent cells accumulate within remodeled pulmonary vascular lesions in pulmonary arterial hypertension (PAH), promoting neighboring cell proliferation and apoptosis resistance through pro-inflammatory signaling. These dysfunctional cells drive the fatal vascular remodeling that current therapies cannot reverse, leading to right heart failure in this devastating condition.
This represents a potentially transformative therapeutic avenue for a disease with extremely limited treatment options and poor prognosis. PAH affects roughly 15-50 people per million globally, with survival rates comparable to many cancers. The precision senotherapy framework proposed here—targeting specific senescent cell types with intermittent dosing at optimal disease stages—could address why early senolytic trials produced conflicting results. The approach acknowledges that not all senescent cells are harmful and timing matters critically. While still preclinical, this targeted cellular housekeeping strategy aligns with emerging longevity medicine principles and could potentially halt or reverse pathologic vascular remodeling rather than merely managing symptoms. The concept of stage-aware, cell-type-specific senolytic interventions may also inform treatment strategies for other age-related vascular diseases where senescent cell accumulation drives pathology.
